5-Amino-1MQ vs Survodutide
A side-by-side research comparison of 5-Amino-1MQ and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-Amino-1MQ | Survodutide |
|---|---|---|
| Full name | 5-Amino-1-Methylquinolinium (NNMT Inhibitor) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Inhibits NNMT enzyme, preventing methylation and degradation of nicotinamide. Increases intracellular NAD+ pools, activates sirtuins, and reduces fat cell size without affecting food intake. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 173.2 Da | 4,500 Da (approximate) |
| Half-life | 8-12 hours | 5-7 days |
| Bioavailability | High (oral) | High (SubQ) |
| Typical dose | 50-100 mg | 0.6-6.0 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Oral (capsule) | Subcutaneous |
5-Amino-1MQ reported benefits
- Increased cellular energy metabolism
- Reduced fat cell size
- Elevated NAD+ levels
- Does not suppress appetite
- Improved muscle stem cell function
- Oral convenience
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.